Immunotherapy is currently one of the most actively pursued areas of research by biotechnology and pharmaceutical companies. “Control of immune activation can save us,” believes Markku Jalkanen, CEO of Faron Pharmaceuticals. Cecilia Stroe, Staff Editor of IPI, explains that at present, the interest in immunotherapy is largely driven by recent compelling efficacy data in cancers with historically bleak outcomes, and by the potential to achieve a cure or functional cure for some patients.
https://international-pharma.com/wp-content/uploads/2016/12/Natural-born….pdf